Melanoma patients receiving a vaccine plus Keytruda had 49% lower recurrence risk than Keytruda alone The combination therapy reduced distant metastasis risk by about 59% in high-risk melanoma patients Personalised mRNA vaccine targets unique tumour markers to boost immune system response against melanoma